ストックスクリーナーアプリを入手
4.31
6.10%
-0.28
アフターアワーズ：
4.31
Bolt Biotherapeutics Inc (BOLT) 最新ニュース
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) grants director options for 5,000 shares - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) director receives 5,000-share stock option grant - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike price - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike - Stock Titan
Bolt Biotherapeutics (BOLT) Declines Over 4%, Nears Critical Support LevelWeekly Profile - newsline.com
Bolt Biotherapeutics (BOLT) Slides 4% Amid Biotech Sector Turbulence – Key Levels to WatchVolume Oscillator - newsline.com
BOLT Q1 2026 Earnings: Deep EPS Miss Highlights Operational ChallengesPost-Earnings Drift - newsline.com
Bolt Biotherapeutics Price Target Announced at $22.00/Share by Rodman & Renshaw - Moomoo
BOLT Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics (BOLT) Gains 2.32%: Biotech Stock Approaches Key Resistance LevelIchimoku Kumo Twist - The Legal Advocate
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating - Investing.com
Bolt Biotherapeutics (BOLT) Edges Higher Amid Tight Trading Range – Support and Resistance Levels in FocusWyckoff Distribution - The Legal Advocate
Bolt Biotherapeutics Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue StageDiluted EPS Report - newsline.com
Bolt Biotherapeutics (BOLT) Slips 1.2% as Shares Test Key Support at $4.65Breadth Thrust - The Legal Advocate
Bolt Biotherapeutics, Inc. (BOLT) reports Q1 loss, lags revenue estimates - MSN
Bolt Biotherapeutics, Inc.Common Stock (NQ: BOLT - The Chronicle-Journal
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics: Cash on Hand Is Expected to Fund Ops Into 2027 - Moomoo
Press Release: Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results - TradingView
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot - marketscreener.com
Bolt Biotherapeutics 1Q 2026: Revenue $26K, Net loss $7.24M, EPS $(4.31) — 10-Q Summary - TradingView
Bolt Biotherapeutics (NASDAQ: BOLT) narrows Q1 loss, cuts expenses - Stock Titan
Cancer drug trial data due in 3Q 2026 as Bolt logs $7.6M operating loss - Stock Titan
BOLT (Bolt Bio) beats earnings estimates as quarterly loss narrows 38 percent, but stock flat.Asset Sale - newser.com
Bolt Biotherapeutics Inc expected to post a loss of $2.85 a shareEarnings Preview - TradingView
BOLT Q1'26 Earnings: EPS estimate is (2.85) USD - TradingView
Bolt Biotherapeutics (BOLT) 2026 proxy details director votes and auditor - Stock Titan
[ARS] Bolt Biotherapeutics, Inc. SEC Filing - Stock Titan
Is Bolt Bio (BOLT) stock moving unpredictably (Trend Strengthens) 2026-04-20Community Pattern Alerts - Cổng thông tin điện tử Tỉnh Sơn La
Operating cash flow per share of Bolt Biotherapeutics, Inc. – MUN:6LP0 - TradingView
Aug Movers: Is Bolt Biotherapeutics Inc still a buy after recent gainsMarket Activity Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Treasury Yields: Will Bolt Biotherapeutics Inc announce a stock splitWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
What is the price target for Bolt Bio (BOLT) Stock | Price at $4.75, Up 5.21%VWAP Deviation - newsline.com
BOLT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is momentum building in Bolt Bio (BOLT) Stock | Price at $4.81, Up 0.63%Linear Regression - newsline.com
Performance Recap: Is Bolt Biotherapeutics Inc still a buy after recent gains2026 Buyback Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
Is Bolt Bio (BOLT) Stock Ready to Drop | Price at $4.56, Up 6.29%TRIN Signal - The Legal Advocate
BOLT Uptrend Accelerates on Market - newser.com
Technical Analysis: Will Bolt Biotherapeutics Inc announce a stock splitTrade Exit Report & Community Consensus Stock Picks - baoquankhu1.vn
Sentiment Watch: Is Bolt Biotherapeutics Inc on track to beat earnings2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Income Plays: Is Bolt Biotherapeutics Inc impacted by rising ratesEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Entry Recap: Is Bolt Biotherapeutics Inc undervalued by DCF analysisInsider Selling & High Conviction Investment Ideas - baoquankhu1.vn
Institution Moves: What is the long term forecast for Bolt Biotherapeutics Inc stock2026 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Fund Flows: Is Bolt Biotherapeutics Inc still a buy after recent gains2026 Breakouts & Weekly Return Optimization Alerts - baoquankhu1.vn
Aug Sectors: What are Bolt Biotherapeutics Incs earnings expectationsTrade Entry Report & AI Powered Market Entry Ideas - baoquankhu1.vn
Momentum Shift: Is Bolt Biotherapeutics Inc still a buy after recent gains2026 Institutional & Stepwise Trade Signal Guides - baoquankhu1.vn
Trend Recap: Will Bolt Biotherapeutics Inc outperform its industry peersWeekly Trade Analysis & Long Hold Capital Preservation Tips - baoquankhu1.vn
Bolt Biotherapeutics discloses new STING agonist immunoconjugates - BioWorld News
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):